HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell.

Abstract
The immunopathogenesis mechanism of dengue virus (DV) infection remains elusive. We previously showed that the target of DV in humans is dendritic cells (DCs), the primary sentinels of immune system. We also observed that despite the significant amount of IFN-alpha induced; DV particles remain massively produced from infected DCs. It suggests that DV may antagonize the antiviral effect of IFN-alpha. Recent work in animal studies demonstrated the differential critical roles of antiviral cytokines, namely IFN-alpha/IFN-beta and IFN-gamma, in blocking early viral production and in preventing viral-mediated disease, respectively. In this study, we examined the effects of IFN-alpha and IFN-gamma in DV infection of monocyte-derived DCs. We showed that the preinfection treatment with either IFN-alpha or IFN-gamma effectively armed DCs and limited viral production in infected cells. However, after infection, DV developed mechanisms to counteract the protection from lately added IFN-alpha, but not IFN-gamma. Such a selective antagonism on antiviral effect of IFN-alpha, but not IFN-gamma, correlated with down-regulated tyrosine-phosphorylation and DNA-binding activities of STAT1 and STAT3 transcription factors by DV. Furthermore, subsequent studies into the underlying mechanisms revealed that DV attenuated IFN-alpha-induced tyrosine-phosphorylation of Tyk2, an upstream molecule of STAT activation, but had no effect on expression of both IFN-alpha receptor 1 and IFN-alpha receptor 2. Moreover, DV infection by itself could activate STAT1 and STAT3 through IFN-alpha-dependent and both IFN-alpha-dependent and IFN-alpha-independent mechanisms, respectively. These observations provide very useful messages with physiological significance in investigation of the pathogenesis, the defense mechanisms of human hosts and the therapeutic considerations in DV infection.
AuthorsLing-Jun Ho, Li-Feng Hung, Chun-Yi Weng, Wan-Lin Wu, Ping Chou, Yi-Ling Lin, Deh-Ming Chang, Tong-Yuan Tai, Jenn-Haung Lai
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 174 Issue 12 Pg. 8163-72 (Jun 15 2005) ISSN: 0022-1767 [Print] United States
PMID15944325 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • DNA-Binding Proteins
  • Interferon-alpha
  • Receptors, Interferon
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Trans-Activators
  • Receptor, Interferon alpha-beta
  • Tyrosine
  • Interferon-gamma
  • Protein-Tyrosine Kinases
  • TYK2 Kinase
  • TYK2 protein, human
Topics
  • Antiviral Agents (antagonists & inhibitors)
  • Cells, Cultured
  • DNA-Binding Proteins (antagonists & inhibitors, biosynthesis, metabolism)
  • Dendritic Cells (immunology, metabolism, virology)
  • Dengue Virus (classification, immunology)
  • Down-Regulation (immunology)
  • Flow Cytometry
  • Humans
  • Interferon-alpha (antagonists & inhibitors, metabolism, physiology)
  • Interferon-gamma (physiology)
  • Phosphorylation
  • Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism, physiology)
  • Receptor, Interferon alpha-beta
  • Receptors, Interferon (biosynthesis)
  • STAT1 Transcription Factor
  • STAT3 Transcription Factor
  • Signal Transduction (immunology)
  • TYK2 Kinase
  • Time Factors
  • Trans-Activators (antagonists & inhibitors, biosynthesis, metabolism)
  • Tyrosine (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: